Bukwang to start preclinical trial for new VEGF inhibitor

Bukwang Pharm said on September 28 it will commence animal experiments for apatinib mesylate, a novel Vascular Endothelial Growth Factor (VEGF) inhibitor and complete the tests in the first half of next year.

To this end, the company signed a contract study agreement with two domestic and foreign clinical research organizations, INA Research Inc. and Biotoxtech Co.

Apatinib mesylate is a ...